FDA Advisory Committee Conflict Policy Takes A Toll; Chairs Plan Response
Executive Summary
Cardiovascular & Renal Drugs Advisory Committee Chair William Hiatt plans to write an editorial concerning the need for a more transparent conflict of interest policy for panel members
You may also be interested in...
Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process
FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than an overhaul of its practices
Hypertension Class Labeling Does Not Release Sponsors From Large Trials
FDA should ensure that manufacturers do not construe the addition of outcomes claims to antihypertensive drug labels as lowering the approval standards for future hypertension agents, members of FDA's Cardiovascular & Renal Drugs Advisory Committee emphasized during an April 26 meeting
Hypertension Class Labeling Does Not Release Sponsors From Large Trials
FDA should ensure that manufacturers do not construe the addition of outcomes claims to antihypertensive drug labels as lowering the approval standards for future hypertension agents, members of FDA's Cardiovascular & Renal Drugs Advisory Committee emphasized during an April 26 meeting